PARIS, July 19 /PRNewswire-FirstCall/ — Cellectis
bioresearch, a specialist in genome customization and a subsidiary
of Cellectis (Alternext: ALCLS), today announced the publication of
a scientific study describing a novel method, based on
meganuclease-driven targeted integration, for the generation of
stable cell lines compatible with high throughput screening
(HTS)(1). The study demonstrated Cellectis bioresearch’s technology
to be faster, more reliable and efficient in deriving cell-based
assays for HTS studies than classical methods. The study has been
published online by Journal of Biomolecular Screening
http://jbx.sagepub.com/cgi/content/abstract/1087057110375115v1.
The development of cell-based assays for HTS approaches is
important to screen molecules on pharmaceutical targets and often
requires the generation of stable cell lines. However, these cell
lines are essentially created by random integration of a gene of
interest (GOI) with no control over the level and stability of gene
expression. In this study, scientists from the Servier Research
institute used Cellectis bioresearch’s cellular Genome Positioning
System, or cGPS®, in CHO-K1 cells, to accomplish targeted
integration of different GOIs. Five different GOIs representing 3
major drug target classes were stably integrated at the same locus
in cGPS® CHO-K1 cells. Characterization of the targeted clones
revealed that the cGPS® CHO-K1 system was more rapid (2-week
protocol), efficient (all selected clones expressed the GOI),
reproducible (GOI expression level variation of 12% maximum), and
stable over time (no change in GOI expr
‘/>”/>